Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors

• Published in: Frontiers in immunology Vol. 14; p. 1197342
• Main Authors: Matsumoto, Kotaro, Suzuki, Katsuya, Takeshita, Masaru, Takeuchi, Tsutomu, Kaneko, Yuko
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.05.2023
• Subjects: Animals; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; biological disease-modifying anti-rheumatic drugs; giant cell arteritis; Giant Cell Arteritis - drug therapy; Immunology; janus kinase inhibitors; Janus Kinase Inhibitors - pharmacology; Janus Kinase Inhibitors - therapeutic use; Mice; molecular remission; Recurrence; takayasu arteritis; Takayasu Arteritis - drug therapy; biological disease-modifying anti-rheumatic drugs; giant cell arteritis; janus kinase inhibitors; molecular remission; takayasu arteritis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1197342

Giant cell arteritis and Takayasu arteritis are two types of primary large-vessel vasculitis (LVV). Although glucocorticoids (GC) are the standard treatment for LVV, the disease relapse rates are high. Recent clinical trials on biological disease-modifying anti-rheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors have demonstrated their efficacy in reducing LVV relapse rates and GC dosages. However, the control of residual inflammation and degenerative alterations in the vessel wall remains an outstanding requirement in the clinical management of LVV. The analysis of immune cell phenotypes in patients with LVV may predict their response to treatment with bDMARDs and JAK inhibitors and guide their optimal use. In this mini-review, we focused on molecular markers, including the immune cell proportions and gene expression, in patients with LVV and in mouse models of LVV treated with bDMARDs and JAK inhibitors.